Concurrent Investment Advisors LLC lessened its holdings in CVS Health Corporation (NYSE:CVS - Free Report) by 71.6% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 13,422 shares of the pharmacy operator's stock after selling 33,826 shares during the period. Concurrent Investment Advisors LLC's holdings in CVS Health were worth $909,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. VAUGHAN & Co SECURITIES INC. purchased a new position in shares of CVS Health in the 1st quarter worth approximately $899,000. Bank of New York Mellon Corp boosted its stake in shares of CVS Health by 2.1% in the 1st quarter. Bank of New York Mellon Corp now owns 8,981,262 shares of the pharmacy operator's stock worth $608,481,000 after buying an additional 183,813 shares during the last quarter. Wayfinding Financial LLC purchased a new position in CVS Health in the first quarter valued at approximately $54,000. Capital Investment Advisory Services LLC lifted its stake in CVS Health by 12.8% in the first quarter. Capital Investment Advisory Services LLC now owns 16,031 shares of the pharmacy operator's stock valued at $1,086,000 after purchasing an additional 1,815 shares during the last quarter. Finally, Argyle Capital Management LLC lifted its stake in CVS Health by 3.1% in the first quarter. Argyle Capital Management LLC now owns 30,217 shares of the pharmacy operator's stock valued at $2,047,000 after purchasing an additional 900 shares during the last quarter. Hedge funds and other institutional investors own 80.66% of the company's stock.
CVS Health Price Performance
CVS traded down $1.08 during trading on Thursday, reaching $65.58. The stock had a trading volume of 6,326,674 shares, compared to its average volume of 10,798,099. The stock has a market cap of $82.96 billion, a PE ratio of 15.65, a PEG ratio of 0.95 and a beta of 0.57. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.63 and a current ratio of 0.82. CVS Health Corporation has a one year low of $43.56 and a one year high of $72.51. The business has a 50-day moving average of $65.18 and a 200-day moving average of $61.93.
CVS Health (NYSE:CVS - Get Free Report) last released its earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 EPS for the quarter, beating analysts' consensus estimates of $1.62 by $0.63. CVS Health had a return on equity of 10.59% and a net margin of 1.39%. The business had revenue of $94.59 billion for the quarter, compared to analysts' expectations of $93.07 billion. During the same quarter in the prior year, the firm earned $1.31 earnings per share. The firm's revenue was up 7.0% on a year-over-year basis. As a group, equities research analysts anticipate that CVS Health Corporation will post 5.89 EPS for the current fiscal year.
CVS Health Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 1st. Stockholders of record on Tuesday, July 22nd will be paid a dividend of $0.665 per share. The ex-dividend date of this dividend is Tuesday, July 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.06%. CVS Health's dividend payout ratio (DPR) is currently 63.48%.
Wall Street Analysts Forecast Growth
Several research firms recently commented on CVS. Robert W. Baird upped their price objective on CVS Health from $51.00 to $71.00 and gave the company a "neutral" rating in a research note on Tuesday, April 15th. Wall Street Zen upgraded CVS Health from a "hold" rating to a "buy" rating in a research note on Friday, May 9th. Jefferies Financial Group upped their price objective on CVS Health from $74.00 to $80.00 and gave the company a "buy" rating in a research note on Monday, June 30th. Truist Financial upped their price objective on CVS Health from $82.00 to $84.00 and gave the company a "buy" rating in a research note on Monday, May 12th. Finally, Mizuho upped their price objective on CVS Health from $70.00 to $76.00 and gave the company an "outperform" rating in a research note on Wednesday, April 9th. Two equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $75.06.
Get Our Latest Stock Report on CVS Health
Insider Activity
In related news, Director Guy P. Sansone acquired 1,570 shares of CVS Health stock in a transaction dated Thursday, June 5th. The shares were purchased at an average cost of $63.70 per share, with a total value of $100,009.00. Following the completion of the purchase, the director owned 12,007 shares of the company's stock, valued at $764,845.90. This represents a 15.04% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.22% of the company's stock.
CVS Health Profile
(
Free Report)
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
Further Reading

Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.